Systemic sclerosis & Raynaud's
Treatment Response Biomarkers for Systemic Sclerosis–Associated Interstitial Lung Disease
Authors' conclusion
Changes in the circulating levels of KL-6 after treatment with MMF or CYC predicted PPF, even after adjusting for baseline factors associated with PPF.
Study context
- Population
- Participants of the Scleroderma Lung Study II (mycophenolate mofetil (MMF) vs CYC for SSc-ILD) with blood samples at baseline and 12 monthsof 142 randomised
- Participants
- 92 participants
- Comparison
- Change in circulating biomarkers in patients who developed progressive pulmonary fibrosis (PPF) vs those who did not
- Primary endpoint
- Association of changes in CRP, IL-6, CXCL4, CCL18 and KL-6 with development of PPF
- Follow-up
- 24 months
Methodological detailslogistic regression
- Logistic regression
Primary result
As reported in the abstract
Change in KL-6 levels · baseline to 12 months
PPF
365.68
mean change · SD 434.41
No PPF
−207.45
mean change · SD 670.26
P < 0.001
Further findings
| Outcome | OR | P value |
|---|---|---|
| Change in KL-6 added to prediction model with baseline factors (sex, baseline reflux severity, CXCL4) | 1.4 | P = 0.0002 |
Changes in C-reactive protein (CRP) and CXCL4 levels, MMF-alone arm (subgroup)
- Changes in CRP and CXCL4 levels were also significantly correlated with PPF
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Treatment Response Biomarkers for Systemic Sclerosis–Associated Interstitial Lung Disease. Arthritis Care Res (Hoboken). Published 15 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →